CoChat
Sign Up
Cited by 441

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Safe harbours for the integration of new DNA in the human genome

Sadelain, Michel, Papapetrou, Eirini P., Bushman, Frederic D.·2012·Nature Reviews Cancer
DOI 10.1038/nrc3179
Open this paper in CoChat — free account

Abstract

Interactions between newly integrated DNA and the host genome limit the reliability and safety of transgene integration for therapeutic cell engineering and other applications. Although targeted gene delivery has made considerable progress, the question of where to insert foreign sequences in the human genome to maximize safety and efficacy has received little attention. In this Opinion article, we discuss 'genomic safe harbours' - chromosomal locations where therapeutic transgenes can integrate and function in a predictable manner without perturbing endogenous gene activity and promoting cancer.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrc3179

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 81

  1. Aiuti, A. et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J. Clin. Invest. 117, 2233–2240 (2007). · DOI
  2. Gaspar, H. B. et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med. 3, 97ra80 (2011).
  3. Riviere, I., Dunbar, C. & Sadelain, M. Hematopoietic stem cell engineering at a crossroads. Blood 17 Nov 2011 (doi:10.1182/blood-2011-09-349993). · DOI
  4. Martin, D. I. & Whitelaw, E. The vagaries of variegating transgenes. Bioessays 18, 919–923 (1996). · DOI · Paper page
  5. Kioussis, D. & Festenstein, R. Locus control regions: overcoming heterochromatin-induced gene inactivation in mammals. Curr. Opin. Genet. Dev. 7, 614–619 (1997). · DOI
  6. Rivella, S. & Sadelain, M. Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. Semin. Hematol. 35, 112–125 (1998).
  7. Bestor, T. H. Gene silencing as a threat to the success of gene therapy. J. Clin. Invest. 105, 409–411 (2000). · DOI
  8. Ellis, J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum. Gene Ther. 16, 1241–1246 (2005). · DOI · Paper page
  9. Karpen, G. H. Position-effect variegation and the new biology of heterochromatin. Curr. Opin. Genet. Dev. 4, 281–291 (1994). · DOI
  10. Weiler, K. S. & Wakimoto, B. T. Heterochromatin and gene expression in Drosophila. Annu. Rev. Genet. 29, 577–605 (1995). · DOI
  11. Nusse, R., van Ooyen, A., Cox, D., Fung, Y. K. & Varmus, H. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 307, 131–136 (1984). · DOI
  12. Schroder, A. R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521–529 (2002). · DOI · Paper page
  13. Wu, X., Li, Y., Crise, B. & Burgess, S. M. Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749–1751 (2003). · DOI · Paper page
  14. Mitchell, R. S. et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2, E234 (2004). · DOI
  15. HaceinBeyAbina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419 (2003). · DOI · Paper page
  16. Ott, M. G. et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nature Med. 12, 401–409 (2006). · DOI
  17. Stein, S. et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nature Med. 16, 198–204 (2010). · DOI
  18. Howe, S. J. et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143–3150 (2008). · DOI · Paper page
  19. Kustikova, O. S. et al. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 102, 3934–3937 (2003). · DOI
  20. Modlich, U. et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 105, 4235–4246 (2005). · DOI
  21. Chang, A. H. & Sadelain, M. The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. Mol. Ther. 15, 445–456 (2007). · DOI
  22. Gijsbers, R. et al. LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol. Ther. 18, 552–560 (2010). · DOI
  23. Modlich, U. et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108, 2545–2553 (2006). · DOI
  24. Emery, D. W. The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum. Gene Ther. 22, 761–774 (2011). · DOI
  25. Persons, D. A. & Baum, C. Solving the problem of gamma-retroviral vectors containing long terminal repeats. Mol. Ther. 19, 229–231 (2011). · DOI
  26. Capecchi, M. R. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nature Rev. Genet. 6, 507–512 (2005). · DOI
  27. Moynahan, M. E. & Jasin, M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nature Rev. Mol. Cell Biol. 11, 196–207 (2010). · DOI
  28. Jasin, M. Genetic manipulation of genomes with rare-cutting endonucleases. Trends Genet. 12, 224–228 (1996). · DOI
  29. Porteus, M. H. & Carroll, D. Gene targeting using zinc finger nucleases. Nature Biotechnol. 23, 967–973 (2005). · DOI · Paper page
  30. Paques, F. & Duchateau, P. Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy. Curr. Gene Ther. 7, 49–66 (2007). · DOI
  31. Boch, J. TALEs of genome targeting. Nature Biotechnol. 29, 135–136 (2011). · DOI
  32. Rosenberg, N., Jolicouer, P., Coffin, J. M., Hughes, S. H. & Varmus, H. E. in Retroviruses 475–586 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA, 1997).
  33. Akagi, K., Suzuki, T., Stephens, R. M., Jenkins, N. A. & Copeland, N. G. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res. 32, D523–D527 (2004). · DOI
  34. Kim, R. et al. Genome-based identification of cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas. J. Virol. 77, 2056–2062 (2003). · DOI
  35. Kohn, D. B., Sadelain, M. & Glorioso, J. C. Occurrence of leukaemia following gene therapy of X-linked SCID. Nature Rev. Cancer 3, 477–488 (2003). · DOI
  36. HaceinBeyAbina, S. et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363, 355–364 (2010). · DOI
  37. Higgins, M. E., Claremont, M., Major, J. E., Sander, C. & Lash, A. E. CancerGenes: a gene selection resource for cancer genome projects. Nucleic Acids Res. 35, D721–D726 (2007). · DOI
  38. Huret, J. L., Minor, S. L., Dorkeld, F., Dessen, P. & Bernheim, A. Atlas of genetics and cytogenetics in oncology and haematology, an interactive database. Nucleic Acids Res. 28, 349–351 (2000). · DOI
  39. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268–274 (2006). · DOI
  40. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011). · DOI · Paper page
  41. Lombardo, A. et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nature Methods 8, 861–869 (2011). · DOI
  42. Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001). · DOI · Paper page
  43. Smit, A. F. Interspersed repeats and other mementos of transposable elements in mammalian genomes. Curr. Opin. Genet. Dev. 9, 657–663 (1999). · DOI · Paper page
  44. Brady, T. et al. Integration target site selection by a resurrected human endogenous retrovirus. Genes Dev. 23, 633–642 (2009). · DOI
  45. Barr, S. D., Leipzig, J., Shinn, P., Ecker, J. R. & Bushman, F. D. Integration targeting by avian sarcoma-leukosis virus and human immunodeficiency virus in the chicken genome. J. Virol. 79, 12035–12044 (2005). · DOI
  46. Kotin, R. M., Linden, R. M. & Berns, K. I. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J. 11, 5071–5078 (1992). · DOI
  47. Henckaerts, E. & Linden, R. M. Adeno-associated virus: a key to the human genome? Future Virol. 5, 555–574 (2010). · DOI · Paper page
  48. Schnepp, B. C., Jensen, R. L., Chen, C. L., Johnson, P. R. & Clark, K. R. Characterization of adeno-associated virus genomes isolated from human tissues. J. Virol. 79, 14793–14803 (2005). · DOI · Paper page
  49. Gao, G. et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl Acad. Sci. USA 100, 6081–6086 (2003). · DOI
  50. Drew, H. R., Lockett, L. J. & Both, G. W. Increased complexity of wild-type adeno-associated virus-chromosomal junctions as determined by analysis of unselected cellular genomes. J. Gen. Virol. 88, 1722–1732 (2007). · DOI
  51. Huser, D. et al. Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome. PLoS Pathog 6, e1000985 (2010). · DOI
  52. McCarty, D. M., Young, S. M., Jr. & Samulski, R. J. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 38, 819–845 (2004). · DOI · Paper page
  53. Mehrle, S., Rohde, V. & Schlehofer, J. R. Evidence of chromosomal integration of AAV DNA in human testis tissue. Virus Genes 28, 61–69 (2004). · DOI
  54. Hernandez, Y. J. et al. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J. Virol. 73, 8549–8558 (1999). · DOI
  55. DeKelver, R. C. et al. Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res. 20, 1133–1142 (2010). · DOI
  56. Zou, J. et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 117, 5561–5572 (2011). · DOI
  57. Ramachandra, C. J. et al. Efficient recombinase-mediated cassette exchange at the AAVS1 locus in human embryonic stem cells using baculoviral vectors. Nucleic Acids Res. 39, e107 (2011). · DOI
  58. Smith, J. R. et al. Robust, persistent transgene expression in human embryonic stem cells is achieved with AAVS1-targeted integration. Stem Cells 26, 496–504 (2008). · DOI
  59. Yang, L. et al. Human cardiovascular progenitor cells develop from a KDR+ embryonicstemcell-derived population. Nature 453, 524–528 (2008). · DOI · Paper page
  60. Hockemeyer, D. et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nature Biotechnol. 27, 851–857 (2009). · DOI
  61. Henckaerts, E. et al. Site-specific integration of adeno-associated virus involves partial duplication of the target locus. Proc. Natl Acad. Sci. USA 106, 7571–7576 (2009). · DOI
  62. Dutheil, N. et al. Characterization of the mouse adeno-associated virus AAVS1 ortholog. J. Virol. 78, 8917–8921 (2004). · DOI
  63. Ogata, T., Kozuka, T. & Kanda, T. Identification of an insulator in AAVS1, a preferred region for integration of adeno-associated virus DNA. J. Virol. 77, 9000–9007 (2003). · DOI
  64. Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367–377 (1996). · DOI · Paper page
  65. Rottman, J. B. et al. Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am. J. Pathol. 151, 1341–1351 (1997).
  66. Lim, J. K., Glass, W. G., McDermott, D. H. & Murphy, P. M. CCR5: no longer a “good for nothing” gene--chemokine control of West Nile virus infection. Trends Immunol. 27, 308–312 (2006). · DOI
  67. Lombardo, A. et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nature Biotechnol. 25, 1298–1306 (2007). · DOI · Paper page
  68. Zambrowicz, B. P. et al. Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. Proc. Natl Acad. Sci. USA 94, 3789–3794 (1997). · DOI
  69. Irion, S. et al. Identification and targeting of the ROSA26 locus in human embryonic stem cells. Nature Biotechnol. 25, 1477–1482 (2007). · DOI
  70. Papapetrou, E. P. et al. Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. Nature Biotechnol. 29, 73–78 (2011). · DOI
  71. Li, Q., Peterson, K. R., Fang, X. & Stamatoyannopoulos, G. Locus control regions. Blood 100, 3077–3086 (2002). · DOI · Paper page
  72. Bejerano, G. et al. Ultraconserved elements in the human genome. Science 304, 1321–1325 (2004). · DOI · Paper page
  73. Fraser, P. Transcriptional control thrown for a loop. Curr. Opin. Genet. Dev. 16, 490–495 (2006). · DOI
  74. Gingeras, T. R. Origin of phenotypes: genes and transcripts. Genome Res. 17, 682–690 (2007). · DOI
  75. Ciuffi, A. et al. Methods for integration site distribution analyses in animal cell genomes. Methods (San Diego, Calif.) 47, 261–268 (2009). · DOI
  76. Gabriel, R. et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nature Med. 15, 1431–1436 (2009). · DOI
  77. Brady, T. et al. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res. 39, e72 (2011). · DOI
  78. Ogino, H., McConnell, W. B. & Grainger, R. M. High-throughput transgenesis in Xenopus using I-SceI meganuclease. Nature Protoc. 1, 1703–1710 (2006). · DOI
  79. Cermak, T. et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39, e82 (2011). · DOI
  80. Papapetrou, E. P. & Sadelain, M. Reconstructing blood from induced pluripotent stem cells. F1000 Med. Rep. 2, 44 (2010). · DOI
  81. Wang, G. P. et al. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood 115, 4356–4366 (2010). · DOI

Cited by

Sorted by citations

Metadata

Authors
Sadelain, M., Papapetrou, E. P., & Bushman, F. D.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2011-12-01
Volume
12
Issue
1
Pages
51-58
ISSN
  • 1474-175X
  • 1474-1768
DOI
10.1038/nrc3179
Cited by
441
References
5
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review